PML Reported In Raptiva User; Genentech Sends “Dear Doctor” Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Finding follows reports of PML in Rituxan, Tysabri patients earlier this year.
You may also be interested in...
Can A REMS Save Raptiva? Tysabri-Style Program Would Mean Restrictions
Ongoing discussions about a risk management plan for Genentech's Raptiva (efalizumab) may provide an avenue to maintain the psoriasis drug's commercial viability, despite its safety problems
Can A REMS Save Raptiva? Tysabri-Style Program Would Mean Restrictions
Ongoing discussions about a risk management plan for Genentech's Raptiva (efalizumab) may provide an avenue to maintain the psoriasis drug's commercial viability, despite its safety problems
Can A REMS Save Raptiva?
FDA issues an advisory after more confirmed cases of PML, but EMEA takes a harder line, recommending suspended marketing of Genentech’s psoriasis treatment.